Louis H. Morrone - 24 Feb 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: EXECUTIVE VICE PRESIDENT
Issuer ticker: ABT
Reported as of: 24 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Feb 2026, 18:52:27 UTC
Prior SEC filing: 01 Jul 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact

Key filing fact

Louis H. Morrone filed Form 4 for ABBOTT LABORATORIES (ABT) on 26 Feb 2026.

Key facts

This page summarizes Louis H. Morrone's Form 4 filing for ABBOTT LABORATORIES (ABT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Feb 2026, 18:52.

Change

Previous filing in this sequence was filed on 01 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867666 Primary reporting owner

Morrone Louis H.

Relationship: EXECUTIVE VICE PRESIDENT
Address: 100 ABBOTT PARK ROAD, ABBOTT PARK
Signature: /s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact
Signature date: 26 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Award

Transaction value: $0
Shares: +15,418
Change %: +23%
Price: $0.000000
Shares after: 82,027
Date: 24 Feb 2026
Ownership: Direct
Footnotes: F1

ABT holding

Common shares without par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12
Date: 24 Feb 2026
Ownership: Profit Sharing Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABT transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +63,561
Change %
Price: $0.000000
Shares after: 63,561
Date: 24 Feb 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 63,561
Exercise price: $114.60
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

Footnote F2

Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

Footnote F3

Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,187 on February 24, 2027, 21,187 on February 24, 2028, and 21,187 on February 24, 2029.